Drugs / Specific T- Lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06027879 | Jan 2024 → Jun 2028 expected | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | Paul Szabolcs | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Specific T- Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06027879 ↗ |
| Modality | Cell therapy | “viral specific T cells” NCT06027879 ↗ |